Infectious Disease Medical Billing Overview
Dr. Elena Park sees the same patient every three months. He is 58, HIV-positive, stable on antiretrovirals, and has been her patient for seven years. On paper, these visits look routine. A quick review of labs, a medication refill, a brief physical. But Dr. Park knows that managing HIV with comorbid diabetes and hypertension, tracking drug resistance patterns, coordinating care across three specialists, and reviewing the latest resistance testing reports is anything but routine. The problem is that her billing reflects the paper version, not the clinical reality. She is billing 99213 for encounters that support 99214 or 99215. That gap, multiplied across a panel of 300 patients, represents tens of thousands of dollars per year in lost revenue.
This is the story of most infectious disease practices. The clinical complexity is extraordinary. The billing often does not reflect it. Infectious disease physicians manage some of the most medically intricate patient populations in medicine: HIV-positive patients on complex antiretroviral regimens, patients with multidrug-resistant tuberculosis, post-transplant recipients with opportunistic infections, and patients recovering from sepsis with long-term sequelae. All of that complexity supports higher E/M code levels, chronic care management billing, transitional care management, and in many cases infusion therapy billing. Capturing all of it requires a billing process built for this specialty.
Common Billing Challenges in Infectious Disease
- E/M level undercoding for chronic infectious disease management: HIV management visits, Hepatitis C treatment monitoring, and long-term antibiotic infusion oversight consistently support 99214 or 99215 under 2021 AMA E/M guidelines, because they involve multiple chronic conditions, review of external laboratory results (resistance testing, viral loads, CD4 counts), and high-risk medication management decisions. Practices that default to 99213 for these visits are systematically underbilling their most common and clinically complex encounter type.
- Infusion therapy billing complexity: Infectious disease practices that administer IV antibiotics in an office setting must bill correctly for drug administration (CPT 96365 for initial infusion, CPT 96366 for each additional hour) and separately for the drug itself under the appropriate J-code (J0696 for ceftriaxone, J2185 for meropenem, J0290 for ampicillin). The drug cost, the administration code, and any concurrent hydration or other infusion services must be correctly sequenced and coded. Commercial payers including Aetna and UnitedHealthcare apply specific bundling rules to infusion claims that differ from Medicare’s rules.
- Antiretroviral therapy prior authorization: Specialty antiretroviral drugs (covered under many plans as specialty pharmacy benefits) frequently require prior authorization from commercial payers including Cigna, Humana, and BCBS. The authorization process for HIV medications often involves step therapy requirements, formulary tier justification, and annual renewals. Gaps in the authorization cycle create prescription interruptions that harm patients and create billing disputes when claims are submitted for authorized drugs that have lapsed.
- COVID-19 and respiratory infection billing transitions: Post-pandemic, the billing landscape for infectious disease changed significantly. Medicare added specific codes for COVID-19 vaccination (CPT 91300-series), testing (CPT 87635 for PCR), and treatment (including monoclonal antibody administration). Many of these billing rules changed multiple times between 2020 and 2024, and practices that did not update their coding protocols are potentially carrying incorrect billing patterns into current claims.
Key CPT Codes for Infectious Disease Billing
- CPT 99215: Established patient office visit, high medical decision making. Appropriate when an infectious disease physician is managing a patient with multiple severe chronic infections, reviewing outside specialist notes and laboratory resistance data, and making decisions about antiretroviral therapy changes or antimicrobial adjustments. Under 2021 AMA guidelines, high MDM requires two or more diagnoses or management options, extensive data review including independent interpretation of test results, or a high-risk management decision such as drug hospitalization risk.
- CPT 96365: Intravenous infusion for therapy, prophylaxis, or diagnosis, initial, up to 1 hour. The primary infusion administration code when IV antibiotics are administered in the office setting. Separately billable from the drug cost (J-code). Requires documentation of start and stop time, drug administered, dose, and route.
- CPT 86703: HIV-1 and HIV-2, single result. The most commonly billed HIV testing code. Covered by Medicare and commercial payers for diagnostic testing and for annual screening in high-risk populations. Medical necessity must be documented through ICD-10 diagnosis coding (Z21 for asymptomatic HIV status, B20 for HIV disease with conditions).
- CPT 87635: Infectious agent detection by nucleic acid (DNA or RNA), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique. The PCR-based COVID-19 test code. Medicare and most commercial payers cover this code for diagnostic testing, though coverage rules for asymptomatic surveillance testing vary by payer and have changed multiple times since 2020.
- CPT 99490: Chronic care management services, at least 20 minutes of clinical staff time per calendar month. Directly applicable to HIV-positive Medicare patients with two or more chronic conditions, which describes the majority of the HIV-positive Medicare population. CCM is systematically underbilled by infectious disease practices despite high patient eligibility rates in their Medicare panels.
Revenue Cycle Considerations for Infectious Disease
The revenue cycle for an infectious disease practice has three distinct streams, each with different dynamics. The first is E/M-based outpatient visits, where the opportunity lies in coding accuracy. The second is infusion therapy administration, where the opportunity lies in correct drug and administration code pairing and payer-specific sequencing rules. The third is care management billing (CCM, TCM), where the opportunity lies in systematic patient identification and process implementation. Most ID practices that work with a specialized billing partner see their fastest revenue gains in care management, because eligibility is high and current billing rates are low.
A/R days for infectious disease practices average 40 to 60 days for E/M claims and somewhat longer for infusion therapy claims, which often require drug cost documentation and payer-specific prior authorization confirmations. Medicaid coverage for HIV medications varies significantly by state: some state Medicaid programs cover a comprehensive antiretroviral formulary with minimal authorization burden, while others impose step therapy and prior authorization requirements that create significant administrative workload.
How My Medical Bill Solution Helps Infectious Disease Practices
Dr. Park’s story does not have to be your story. My Medical Bill Solution works with infectious disease practices to identify the specific revenue gaps in their billing process and close them. We conduct E/M coding reviews against 2021 AMA guidelines across your encounter data, identify eligible Medicare patients for CCM enrollment, build correct infusion therapy billing protocols for your drug mix, and manage the antiretroviral prior authorization cycle so your patients stay on therapy without administrative interruptions. When payers deny an infusion claim or downcode an HIV management visit, we respond with the clinical documentation that gets the correct payment. Contact My Medical Bill Solution today and let us show you what your practice should be collecting.